Clinical Trial Update: Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 study of denosumab in high-risk smoldering multiple myeloma and SLiM-CRAB positive early multiple myeloma patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED